BAM
KPTI icon

Belpointe Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Belpointe Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-67
Closed -$3.89K – 2076
2023
Q1 		$3.89K Hold
67
– – ﹤0.01% 3101
2022
Q4 		$3.4K Buy
+67
New +$4.64K ﹤0.01% 3068

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Belpointe Asset Management's KPTI Position: Q2 2023 in Review

Belpointe Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 67 shares — an estimated $3.89K sold.

Belpointe Asset Management first reported a position in KPTI in Q4 2022 and held it in 2 quarters. The position peaked at $3.89K in Q1 2023. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Belpointe Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 67 Karyopharm Therapeutics shares in Q2 2023, an estimated $3.89K.
  • Belpointe Asset Management first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Karyopharm Therapeutics position peaked at $3.89K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.